BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3884747)

  • 1. The effect of administration rate on cisplatin-induced emesis.
    Jordan NS; Schauer PK; Schauer A; Nightingale C; Golub G; Martin RS; Williams HM
    J Clin Oncol; 1985 Apr; 3(4):559-61. PubMed ID: 3884747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.
    Warrington PS; Allan SG; Cornbleet MA; MacPherson JS; Smyth JF; Leonard RC
    Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1334-7. PubMed ID: 3790968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
    Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
    J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis.
    Agostinucci WA; Gannon RH; Golub GR; Martin RS; Schauer PK; Dinonno EB
    Clin Pharm; 1988 Jun; 7(6):454-7. PubMed ID: 3402181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.
    Gralla RJ; Itri LM; Pisko SE; Squillante AE; Kelsen DP; Braun DW; Bordin LA; Braun TJ; Young CW
    N Engl J Med; 1981 Oct; 305(16):905-9. PubMed ID: 7024807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
    Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW
    Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
    Hainsworth JD; Hesketh PJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion versus intermittent short infusion of metoclopramide for cisplatin-induced acute emesis.
    Saito H; Shimokata K; Yamori S; Kajita M; Niimi T
    Am J Clin Oncol; 1994 Oct; 17(5):422-6. PubMed ID: 8092115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Randomized control study of high-dose metoclopramide in the prevention of CDDP-induced emesis].
    Sawamura N; Funaki Y; Takahashi S; Yokoyama S; Fujita J; Futami H; Sasaki Y; Yoshioka S; Sakurai M; Eguchi K
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):943-6. PubMed ID: 3885865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
    Grunberg SM; Gala KV; Lampenfeld M; Jamin D; Johnson K; Cariffe P; Strych D; Krailo M
    J Clin Oncol; 1984 Jul; 2(7):782-7. PubMed ID: 6539812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study.
    Carr BI; Bertrand M; Browning S; Doroshow JH; Presant C; Pulone B; Hill LR
    J Clin Oncol; 1985 Aug; 3(8):1127-32. PubMed ID: 4040552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy.
    McDermed JE; Cohen JL; Joseph C; Strum SB
    J Clin Oncol; 1985 Oct; 3(10):1400-8. PubMed ID: 3900303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
    Nino S; Umehara H; Inoue I; Tamura T; Sasaki Y; Sakurai M; Shinkai T; Eguchi K; Saijo N; Suemasu K
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2881-4. PubMed ID: 3310905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
    Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
    N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer.
    Passalacqua R; Cocconi G; Caminiti C; Silingardi V; Bella MA; Bichisao E; Michiara M; Malavasi V; Donati D; Di Costanzo F; Rocca A; Di Sarra S; Scaglione F; Fraschini F
    J Clin Oncol; 1997 Jun; 15(6):2467-73. PubMed ID: 9196163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
    Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis.
    Lee CW; Suh CW; Lee JS; Lee KH; Cho GY; Kim SW; Kim SH
    J Korean Med Sci; 1994 Oct; 9(5):369-75. PubMed ID: 7702784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.